Conscience, a Canadian non-profit organization, is dedicated to promoting drug discovery through open science to enhance access to treatments. Recently, the organization announced its support for two significant projects aimed at addressing childhood rare diseases by improving early diagnosis and treatment options.
The first project involves a multi-centre Phase 1/2 clinical trial for a gene therapy targeting CLN7 Batten disease, which is characterized as a fatal ultra-rare genetic disorder affecting children. The trial aims to assess the efficacy and safety of the gene therapy as a potential treatment. The importance of this project lies in its focus on providing a much-needed intervention for affected children and their families.
In addition to the clinical trial, Conscience is also supporting a second initiative aimed at expanding the availability of treatment options for children suffering from various rare diseases. This project is expected to benefit from collaboration among researchers and healthcare professionals dedicated to enhancing the landscape of care for these patients. These initiatives reflect a growing commitment within the medical community to address the challenges posed by rare diseases in children and ensure that timely diagnosis and appropriate therapies are accessible.
Analyzed Canadian Outlets (1)
1 headline